GlassScriptPhysician profile
Leedylyn Stadulis
NPI 1245221100
$4,364.01
in general payments reported to CMS, 2019-2025
38 companies · $539 in 2025
The $539 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $294 · 2021: $811 · 2022: $1,149 · 2023: $610 · 2024: $482 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $570.22 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $525.61 | 2019-2025 | Veozah |
| Pfizer INC. | $372.09 | 2019-2025 | |
| Exeltis, USA INC. | $371.12 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $335.96 | 2019-2025 | |
| Organon LLC | $227.22 | 2021-2025 | Nexplanon |
| Aspira Women'S Health INC | $218.55 | 2022-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $191.37 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $185.67 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Mayne Pharma Commercial LLC | $149.30 | 2021-2025 | |
| Therapeuticsmd, INC. | $104.63 | 2019-2021 | |
| Exact Sciences Corporation | $102.55 | 2024-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $97.31 | 2022-2024 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Merck Sharp & Dohme LLC | $89.91 | 2019-2021 | |
| Optumhealth Care Solutions, LLC | $84.34 | 2023-2024 | Vivify Health Care Team Portal, Zyno Solutions, Eitan Medical |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $79.90 | 2019-2022 | |
| Biogen, INC. | $74.82 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $51.82 | 2021-2022 | |
| Shield Therapeutics INC | $51.43 | 2024 | |
| Scynexis, INC. | $50.77 | 2022 | |
| Evofem Biosciences, INC. | $47.70 | 2021-2022 | |
| Roche Diagnostics Corporation | $39.54 | 2019-2021 | |
| Ethicon US, LLC | $38.20 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $37.82 | 2022 | |
| Smith+Nephew, INC. | $35.72 | 2019-2021 | |
| Millicent US INC | $31.58 | 2020 | |
| Lupin INC. | $26.30 | 2019 | |
| Allergan, INC. | $24.68 | 2019 | |
| Medtronic, INC. | $17.59 | 2022 | |
| Avanos Medical | $16.66 | 2019 | |
| Duchesnay USA Incorporated | $16.55 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.20 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.61 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $14.23 | 2022 | |
| Mission Pharmacal Company | $13.80 | 2019 | |
| Agile Therapeutics, INC. | $13.46 | 2021 | |
| Dysis Medical, INC. | $12.51 | 2021 | |
| Medtronic USA, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leedylyn Stadulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.